michel_porro-getty_images

Zynerba’s cannabis-based transdermal patch fails at Phase 1, shares slide 21%

pharmafile | July 6, 2018 | News story | Medical Communications, Research and Development |  GW Pharma, Zynerba, cannabidinol, cannabinol, cannabis, pharma, trial failure 

As public focus on the issue of medicinal cannabis continues to grow, Zynerba Pharmaceuticals has announced that its transdermal tetrahydrocannabinol (THC) patch ZYN001 has failed in Phase 1 trials to achieve targeted levels of THC in the blood of patients.

Zynerba attempted to assess the efficacy of a range of dosages and wear times in 60 participants, who wore the patches for a duration of between 24 hours and two weeks, but the drug did not hit the target levels of 5ng/ml to 15ng/ml of THC. The news caused the company shares to plummet 21%.

However, the company did note that the treatment was well tolerated, with no serious adverse of events or discontinuations and minimal skin erythema.

Advertisement

The disappointing news comes just weeks after the breakthrough news that the FDA decided to approve GW Pharma’s Epidiolex (cannabidiol) as an adjunctive therapy in the treatment of seizures in patients with Lennox-Gastaut syndrome or Dravet syndrome. The move marked the first approval in the US of a drug product derived from the controlled substance cannabis.

Given the bad news, Zynerba has confirmed it will now shift focus onto its othercandidatye, ZYN002, in the treatment of Fragile X syndrome, developmental and epileptic encephalopathy, and adult refractory epilepsy.

Matt Fellows

Related Content

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

blood_test

Johnson & Johnson announces successful results from trial for myeloma treatment

Global healthcare company, Johnson & Johnson, announced that analysis of its Darzalex (daratumumab) therapy showed …

Bend Bioscience adds commercial spray drying facility to Georgia site

Bend Bioscience has announced the addition of a commercial-scale spray dryer and a Gerteis dry …

The Gateway to Local Adoption Series

Latest content